Orexigen Sheds LIGHT On Potential CV Benefit For Contrave
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech disclosed in an SEC filing that its obesity drug may actually provide a cardiovascular benefit to patients based on early results from an ongoing outcomes study.